title: Di-K19Hc, an antimicrobial peptide as new ototopical agent for treatment of otitis media.
abstract: CONCLUSIONS
  Di-K19Hc is a promising new ototopical antibiotic for treatment of middle ear infections associated with antibiotic-resistant bacteria.
  
  
  OBJECTIVE
  Di-K19Hc was previously shown to exert profound antimicrobial activity against a variety of antibiotic-resistant bacteria and fungi. In this study, we evaluated the potential use of di-K19Hc as a topical agent for the treatment of otitis media (OM) caused by a variety of microbial pathogens including bacteria resistant to conventional antibiotics.
  
  
  METHODS
  Antimicrobial activity of di-K19Hc was measured by colony count assay. Hearing threshold was determined by measurement of auditory brainstem response in mice treated with di-K19Hc. Mice treated with gentamicin were used as a control.
  
  
  RESULTS
  Di-K19Hc showed much stronger antimicrobial activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa associated with human OM than did ofloxacin. Also, it was shown that the peptide exhibited substantial dose-dependent antimicrobial activity against microbes from middle ear fluid of patients with OM. Topically applied di-K19Hc caused neither a decrease of hearing level nor loss of hair cells.
authors.affiliation: Department of Biotechnology, Hoseo University, Asan, Chungnam-Do, Korea.
authors.forename: Young Shin
authors.initials: YS
authors.lastname: Lee
authors.forename: Young-Jin
authors.initials: YJ
authors.lastname: Kim
authors.forename: Seung Hyo
authors.initials: SH
authors.lastname: Choi
authors.forename: Kyoung Hwa
authors.initials: KH
authors.lastname: Shin
authors.forename: Woong Sik
authors.initials: WS
authors.lastname: Jang
authors.forename: In Hee
authors.initials: IH
authors.lastname: Lee
authors.forename: Jong Woo
authors.initials: JW
authors.lastname: Chung
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023181:Antimicrobial Cationic Peptides / Q000008:administration & dosage / Q000009:adverse effects*; D004353:Drug Evaluation, Preclinical; D006198:Hair Cells, Auditory / Q000187:drug effects; D006309:Hearing / Q000187:drug effects*; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D010033:Otitis Media / Q000188:drug therapy*; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013203:Staphylococcal Infections / Q000188:drug therapy; D018675:Toxicity Tests
chemical_list: D000890:Anti-Infective Agents; D023181:Antimicrobial Cationic Peptides; C553095:di-K19Hc peptide